EVMN
Evommune, Inc.Healthcare·Biotechnology
$23.23
$329M market cap
Revenue
$0.0M
Free Cash Flow
$-44.4M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
2-Year Price History
$22.87+24.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -23.6 | -24.0 | -21.7 | -27.5 | -27.6 | -0.1 | 211.5 | 9.1 | 33.7 | -55.1% | -- | -- |
| Act | 2025-Q4 | 0.0 | -29.4 | -29.7 | -28.3 | -16.7 | -16.8 | -0.1 | 149.2 | 2.1 | 31.5 | -172.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$23.23
Market Cap$329M
Enterprise Value$127M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-13.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-50.0M
Free Cash Flow$-44.4M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-113.9%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.3M
Days to Cover13.3
Change (vs Prior)-6.1%
Need at least 2 settlement dates for chart
Employees
Headcount45
Revenue / Employee$0
Gross Profit / Employee$-7,756
Cash Runway
57.2months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
225.5%(+90.1% YoY)
75 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
12.2%(+8.1% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | $113M | $17.12 | +$0 | +$113M | -18.7% | $1.02B |
| RA CAPITAL MANAGEMENT, L.P. | $80.3M | $17.18 | +$825K | +$80.3M | -4.4% | $9.44B |
| Pivotal bioVenture Partners Investment Advisor LLC | $44.3M | $17.12 | +$0 | +$44.3M | +1.4% | $280M |
| Andera Partners | $43.6M | $17.12 | +$0 | +$43.6M | -18.3% | $177M |
| RTW INVESTMENTS, LP | $34.5M | $17.97 | +$5.0M | +$34.5M | -2.2% | $9.26B |
| MPM BioImpact LLC | $33.5M | $22.53 | +$30.9M | +$33.5M | -1.8% | $1.29B |
| Nan Fung Group Holdings Ltd | $33.1M | $17.12 | +$0 | +$33.1M | -4.7% | $120M |
| JPMORGAN CHASE & CO | $32.1M | $17.73 | +$3.5M | +$32.1M | -0.2% | $1.47T |
| SymBiosis Capital Partners, LLC | $29.4M | $17.12 | +$0 | +$29.4M | -15.2% | $52.8M |
| EVENTIDE ASSET MANAGEMENT, LLC | $27.8M | $18.32 | +$5.7M | +$27.8M | -1.6% | $5.96B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $25.7M | $18.89 | +$7.7M | +$25.7M | -0.2% | $864.93B |
| JANUS HENDERSON GROUP PLC | $20.6M | $22.99 | +$20.6M | +$20.6M | +1.2% | $209.29B |
| MARSHALL WACE, LLP | $20.2M | $17.12 | −$2.5M | +$20.2M | +0.6% | $92.71B |
| BAKER BROS. ADVISORS LP | $19.5M | $22.99 | +$19.5M | +$19.5M | -0.5% | $16.13B |
| Alyeska Investment Group, L.P. | $16.7M | $22.99 | +$16.7M | +$16.7M | -0.5% | $35.33B |
| Defilade Capital Management, L.P. | $15.6M | $21.13 | +$10.6M | +$15.6M | +1.9% | $680M |
| BlackRock, Inc.Passive | $15.5M | $21.75 | +$12.2M | +$15.5M | -0.2% | $5.69T |
| Kynam Capital Management, LP | $14.4M | $21.25 | +$10.1M | +$14.4M | +0.5% | $1.58B |
| SECTORAL ASSET MANAGEMENT INC | $13.5M | $17.12 | +$0 | +$13.5M | -0.9% | $117M |
| Verition Fund Management LLC | $12.6M | $17.12 | −$350K | +$12.6M | -0.4% | $9.73B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-3.82%
avg per quarter
Holders (ex-self)
-5.25%
excl. this stock
Buyers (this Q)
-0.69%
63 buyers · $0.27B in
Sellers (this Q)
+1.73%
11 sellers · $-0.00B out
alpha coverage: 98% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-4.5%
how holders react when this stock falls
On quiet Qs
-3.3%
−10% to +10% baseline
On rallies (+10%+)
+3.8%
how they react when this stock rises
Holders' portfolio flow this Q
+1.4%
inflows — adds are organic
Sellers' portfolio flow this Q
-45.2%
Sellers shed AUM broadly — partly forced.
Biggest decreases this quarter
Aberdeen Group plcexited−$9.0MSofinnova Investments, Inc.exited−$2.6MMARSHALL WACE, LLP−$2.5Mα+0.6Velan Capital Investment Management LP−$1.4Mα-5.6BALYASNY ASSET MANAGEMENT LLCexited−$1.1MCapricorn Fund Managers Ltdexited−$1.0MCITADEL ADVISORS LLCexited−$866KTUDOR INVESTMENT CORP ET ALexited−$547KQube Research & Technologies Ltdexited−$412KTWO SIGMA INVESTMENTS, LPexited−$365K
New buyers this quarter
Top-5 holders · 39.8%
EQT Fund Management S.a r.l.--
RA CAPITAL MANAGEMENT, L.P.--
Pivotal bioVenture Partners Investment Advisor LLC--
Andera Partners--
RTW INVESTMENTS, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
EQT Fund Management S.a r.l.4.9MRA CAPITAL MANAGEMENT, L.P.3.5MPivotal bioVenture Partners Investment Advisor LLC1.9MAndera Partners1.9MRTW INVESTMENTS, LP1.5MMPM BioImpact LLC1.5MNan Fung Group Holdings Ltd1.4MJPMORGAN CHASE & CO1.5MSymBiosis Capital Partners, LLC1.3MEVENTIDE ASSET MANAGEMENT, LLC1.2M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$55.0013680.0%
Last Year (10 analysts)$46.409970.0%
Current Price$23.23
Analyst Ratings
3
Buy: 3Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
12.9%retail-3.6pp
27.0%dark-1.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.